1 unchanged sentence
Insider Adoption or Termination of Trading Arrangements:
−Removed: During the fiscal quarter ended March 31, 2024, none of our directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K, except as described in the table below:
+Added: During the fiscal quarter ended June 30, 2024, none of our directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K, except as described in the table below:
Aggregate Number of Shares of Common Stock to be Sold Pursuant to Trading Arrangement
−Removed: Greg Zante , Chief Financial Officer
−Removed: February 2, 2024
+Added: Brian Lian , President, Chief Executive Officer and Director
Rule 10b5-1 trading arrangement
August 8, 2025 (1)
−Removed: Marianne Mancini , Chief Operations Officer
−Removed: February 1, 2024
+Added: Matthew Singleton , Director
trading arrangement
−Removed: April 20, 2025 (1)
+Added: August 14, 2026 (1)
+Added: Rouan , Ph.D., Director
+Added: Rule 10b5-1 trading arrangement
+Added: August 19, 2025 (1)
+Added: Lawson Macartney, Ph.D ., Director
+Added: Rule 10b5-1 trading arrangement
+Added: February 21, 2025 (1)
The trading arrangement permits transactions through and including the earlier to occur of (a) the date that all shares subject to the trading arrangement have been sold and (b) the date listed in the table.
2 unchanged sentences
Form of Common Stock Certificate.
+Added: Master License Agreement, dated May 21, 2014, by and among Viking Therapeutics, Inc., Ligand Pharmaceuticals Incorporated and Metabasis Therapeutics, Inc.
+Added: First Amendment to Master License Agreement, dated September 6, 2014, by and among Viking Therapeutics, Inc., Ligand Pharmaceuticals Incorporated and Metabasis Therapeutics, Inc.
+Added: Second Amendment to Master License Agreement, dated April 8, 2015, by and among Viking Therapeutics, Inc., Ligand Pharmaceuticals Incorporated and Metabasis Therapeutics, Inc.
+Added: Viking Therapeutics, Inc.
+Added: 2024 Equity Incentive Plan.
+Added: Form of Stock Option Award Agreement under the Viking Therapeutics, Inc.
+Added: 2024 Equity Incentive Plan.
+Added: Form of Restricted Stock Unit Award Agreement under the Viking Therapeutics, Inc.
+Added: 2024 Equity Incentive Plan.
+Added: Form of Restricted Stock Award Agreement under the Viking Therapeutics, Inc.
+Added: 2024 Equity Incentive Plan.
+Added: 2024 Employee Stock Purchase Plan.
Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934.
3 unchanged sentences
Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
−Removed: Inline XBRL Taxonomy Extension Schema Document.
−Removed: Inline XBRL Taxonomy Extension Calculation Linkbase Document.
−Removed: Inline XBRL Taxonomy Extension Definition Linkbase Document.
−Removed: Inline XBRL Taxonomy Extension Label Linkbase Document.
−Removed: Inline XBRL Taxonomy Extension Presentation Linkbase Document.
+Added: Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents.
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
Attached as Exhibit 101 to this report are the following formatted in iXBRL (Inline Extensible Business Reporting Language):
−Removed: (i) Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023, (ii) Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024 and 2023, (iii) Consolidated Statements of Stockholders’ Equity (Deficit) for the three months ended March 31, 2024 and 2023, (iv) Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023, and (v) Notes to Consolidated Financial Statements.
+Added: (i) Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023, (ii) Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2024 and 2023, (iii) Consolidated Statements of Stockholders’ Equity (Deficit) for the three and six months ended June 30, 2024 and 2023, (iv) Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023, and (v) Notes to Consolidated Financial Statements.
+Added: * Filed herewith.
+Added: Certain identified information has been omitted pursuant to Item 601(b)(10) of Regulation S-K because such information is both (i) not material and (ii) information that the Registrant treats as private or confidential.
+Added: The Registrant hereby undertakes to furnish supplemental copies of the unredacted exhibit upon request by the SEC.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Viking Therapeutics, Inc.
−Removed: April 24, 2024
+Added: July 24, 2024
/s/ Brian Lian, Ph.D.
2 unchanged sentences
(Principal Executive Officer)
−Removed: April 24, 2024
+Added: July 24, 2024
/s/ Greg Zante
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.